A high lipid core burden in non-revascularized plaque is associated with nearly a 13-fold higher risk of major adverse cardiovascular events (MACEs) such as cardiac death and myocardial infarction (MI), according to new research based on coronary computed tomography angiography (CCTA) findings.
Emerging research, based on coronary computed tomography angiography (CCTA) findings, suggests that a lipid core burden greater than or equal to 2.8 percent in patients with non-ST-segment elevation (NSTE) acute coronary syndrome (ACS) is associated with significantly elevated risk for major adverse cardiovascular events (MACEs).
For the multicenter prospective study, recently published in Radiology, researchers reviewed data from 342 patients with NSTE ACS (mean age of 57.9) who had CCTA exams within a day of undergoing invasive coronary angiography (ICA).
Data from a median follow-up period of four years revealed that 29.7 percent of the study cohort had MACEs, ranging from 41 hospitalizations for unstable angina to eight cardiac deaths. The researchers also noted that MACEs related to non-revascularized plaque occurred in 23.9 percent of the cohort.
The study findings showed that those with MACEs related to non-revascularized plaque had significantly higher lipid core volume (37.6 mm3 vs. 7.3 mm3) and lipid core burden (12.8 percent vs. 3.8 percent) in comparison to study participants who did not have non-revascularized plaque-related MACEs. The researchers also noted a 12.6 hazard ratio for MACEs in participants with a lipid core burden greater than or equal to 2.8 percent in comparison to those who had less than a 2.8 percent lipid core burden.
“In our study, plaque-level lipid core burden and volume were both independent predictors of future non-revascularized plaque-related MACEs, suggesting that lipid-rich plaques were at high risk for future adverse events,” wrote study co-author Bin Lu, M.D., a professor and director of the Department of Radiology at Fuwai Hospital, Peking Union Medical College and the Chinese Academy of Medical Sciences in Beijing, China, and colleagues.
Noting challenges and risks with three-vessel intravascular imaging, the researchers suggested the use of software (Frontier, Siemens Healthineers) that can quantify plaque on CCTA could facilitate more efficient and accurate risk assessment.
“With the development of semiautomatic software for quantification of plaque information at CCTA, it is possible to quantify lipid core burden and volume rapidly,” emphasized Lu and colleagues. “In the current study, the interclass correlation coefficients ranged from 0.74 to 0.86 for interobserver and intra-observer agreement of lipid core burden and volume at the participant and plaque levels, reflecting the robustness of the software.”
In regard to study limitations, the researchers acknowledged that the diagnosis of NSTE ACS in all study participants may limit extrapolation of the study findings to patients with chronic coronary syndrome, ST-elevation myocardial infraction or very high-risk NSTE ACS.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.